The New England Journal of Medicine (NEJM) is a weekly general medical journal that publishes new medical research and review articles, and editorial opinion on a wide variety of topics of ...

May 11, 2025 · In this phase 3b, open-label, controlled trial, adult participants with obesity but without type 2 diabetes were randomly assigned in a 1:1 ratio to receive the maximum …

Mar 1, 2025 · Tezepelumab is a human monoclonal antibody that specifically blocks TSLP from interacting with its heterodimeric receptor. 21,22 Tezepelumab administered subcutaneously …

Apr 28, 2025 · In cohort 1, a total of 75 patients received zongertinib at a dose of 120 mg. At the data cutoff (November 29, 2024), 71% of these patients (95% confidence interval [CI], 60 to …

The New England Journal of Medicine publishes high-quality medical research, reviews, and opinions to advance medical science and improve patient care.

Mar 30, 2025 · Elevated lipoprotein(a) concentrations are associated with atherosclerotic cardiovascular disease. The safety and efficacy of lepodisiran, an extended-duration, small …

Feb 12, 2025 · Anti‐ PF4 mediated thrombocytopenia and thrombosis associated with acute cytomegalovirus infection displays both HIT ‐like and VITT ‐like characteristics , British Journal …

Apr 23, 2025 · Uncontrolled hypertension remains a leading cause of cardiovascular complications and death from cardiovascular disease. 1 Despite the use of multidrug …

Apr 23, 2025 · A total of 1721 patients (1680 adults and 41 adolescents) underwent randomization and received brensocatib or placebo. The annualized rate of pulmonary …

3 days ago · Explore this issue of The New England Journal of Medicine (Vol. 0 No. 0).